Real world clinical experience of Chronic Hepatitis B Treatment in SSA

Author:

Bane Abate1,Sultan Amir1,Tibebu Zebeaman2,Ahmed Rabia2

Affiliation:

1. Addis Ababa University

2. Adera Medical Center

Abstract

Abstract Background About three hundred fifty to four hundred million people are infected chronically with hepatitis B worldwide and about 780,000 people die annually of its complications. Ethiopia is located in the region of hepatitis B hyper-endemicity ranging from, 8–12%. However, up to 17% of HBV, infected patients present for care late with liver cirrhosis in sub-Saharan Africa (SSA). Fortunately, antiviral therapy of CHB has shown to be effective in preventing complications and improving survival even at stage of early cirrhosis. The goal of therapy is to decrease the morbidity and mortality associated with CHB. Tenofovir disoproxil fumarate (TDF) is among the oral antiviral approved for the treatment of CHB. TDF treatment has shown to be effective in a wider pool of the CHB populations. Literatures indicate long-term TDF treatment was associated with sustained virologic, biochemical, and serologic responses. Objectives To assess the outcome of TDF treatment of Chronic Hepatitis B patients at Adera Medical center in Addis Ababa, Ethiopia. Methods Hospital-based retrospective cross-sectional study was employed. Hundred forty-four CHB patients on TDF treatment were enrolled. Sociodemographic, clinical, and laboratory parameters were collected. The data was entered and analyzed using SPSS (SPSS, Version 23). Results The mean age of the participants is 35.52 ± 10.34. Three fourth of the patients (76.4%) are male. Fifteen patients have progressed to decompensation at the end of the study period. 93.1% of the participants are HBeAg negative, while 5.6% have attained loss of HBsAg on TDF A significant association (p < 0.01) between APRI improvement, with the duration of treatment, and baseline viral load was found. Paired sample t-test showed an improvement in the mean APRI score of 0.2 (CI: 0.07–0.367; p < 0.01). Conclusion TDF is safe and effective in reducing viral load and complications among our patients. Not only did it show benefits in improving liver parameters and suppression of viral load, but also it has attained a functional cure in some patients.

Publisher

Research Square Platform LLC

Reference30 articles.

1. Ethiopia |. Coalition for Global Hepatitis Elimination [Internet]. [cited 2022 Feb 16]. Available from: https://www.globalhep.org/country-progress/ethiopia.

2. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology. 2018 Jun 1;3(6):383–403.

3. Bishop N. Hepatitis B, [Internet]. Vol. 19, On Continuing Practice. 1992 [cited 2022 Apr 23]. p. 35–8. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.

4. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver international: official journal of the International Association for the Study of the Liver. 2016 Sep 1;36(9):1239–51.

5. Hepatitis B. [Internet]. [cited 2022 Feb 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3